Table 1.
Demographics and Acinetobacter baumanii prevalence in the intensive care unit and hospital before and after intervention (cases per 1000 admissions)
| Before intervention (period 1) | One year postintervention (period 2) | Two years postintervention (period 3) | |
|---|---|---|---|
| ICU admissions (n) | 513 | 516 | 537 |
| Age (years) | 61 ± 20.2 | 50 ± 21.7 | 59 ± 21.2 |
| Gender (male) | 277 (54%) | 300 (58.1%) | 306 (57%) |
| APACHE II score | 18.3 ± 8.1 | 18.4 ± 8.1 | 18.3 ± 8.0 |
| Median ICU length of stay (days) | 3 (2–6) | 3 (2–7) | 3 (2–6) |
| ICU mortality | 58 (11.3%) | 52 (10%) | 50 (9%) |
| CRAB patients | |||
| CRAB ICU acquisitiona | 54.6 (n = 28) | 1.9 (n = 1)b | 5.6 (n = 3)b |
| CRAB carriers discharged alive from ICU to hospital wardsa | 58.5 (n = 30) | 1.9 (n = 1)b | 7.4 (n = 4)b |
| CRAB ICU admission prevalencea | 56.5 (n = 29) | 5.8 (n = 3)b | 13.0 (n = 7)b |
| Median ICU length of stay (days) | 13 (5–22) | 7 (3–28)c | |
| Median time from ICU admission until CRAB acquisition (days) | 7 (4–11) | 4 (3–32)c | |
| CRAB hospital mortality | 31/57 (54%) | 4/4 (100%) | 6/10 (60%) |
| Medical and surgical wards | |||
| Admissions (n) | 39,444 | 41,006 | 44,113 |
| Hospital wards CRAB prevalencea (clinical cultures) | 4.4 (n = 173) | 2.4 (n = 99)b | 2.5 (n = 111)b |
Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II, CRAB Carbapenem-resistant Acinetobacter baumanii, ICU Intensive care unit
aCases/1000 admissions
bp < 0.001 for comparison with preintervention period
cOne and two years postintervention combined owing to small numbers, p = ns compared to preintervention period